ReviewF1000Research2016
Respiratory syncytial virus infection: an innate perspective.
Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Innate airway responses shape permissiveness to human respiratory syncytial virus.Virus research · 2026Article
- Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control.Medicinal research reviews · 2026Review
- Distinct Cytokine Landscapes Induced by Influenza a Virus, RSV, and SARS-CoV-2 in Older Adults (65+) Using an Ex Vivo Whole Blood Stimulation Model.Pathogens (Basel, Switzerland) · 2026Article
- Natural Killer Cells Are Dispensable for Virus Control in Rag2European journal of immunology · 2025Article
- Host Immune Response to Respiratory Syncytial Virus Infection in Children.Influenza and other respiratory viruses · 2025Review
- Immunomodulation in Respiratory Syncytial Virus Infection: Mechanisms, Therapeutic Targets, and Clinical Implications.Microorganisms · 2025Review
- Vaccines for Respiratory Viruses-COVID and Beyond.Vaccines · 2024Review
- Review
- The Use of Precision-Cut Lung Slices for Studying Innate Immunity to Viral Infections.Current protocols · 2022Article
- Type I interferons and MAVS signaling are necessary for tissue resident memory CD8+ T cell responses to RSV infection.PLoS pathogens · 2022Article
- Prediction of the Active Components and Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Neutrophils in respiratory viral infections.Mucosal immunology · 2021Review
- Melatonin potentials against viral infections including COVID-19: Current evidence and new findings.Virus research · 2020Review
- Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.Antimicrobial agents and chemotherapy · 2020Article
- MAVS Deficiency Is Associated With a Reduced T Cell Response Upon Secondary RSV Infection in Mice.Frontiers in immunology · 2020Article
- Mathematical modelling identifies the role of adaptive immunity as a key controller of respiratory syncytial virus in cotton rats.Journal of the Royal Society, Interface · 2019Article
- Neutrophil recruitment and activation are differentially dependent on MyD88/TRIF and MAVS signaling during RSV infection.Mucosal immunology · 2019Article
- Macrophage migration inhibitory factor (MIF) controls cytokine release during respiratory syncytial virus infection in macrophages.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Article
- Host Components Contributing to Respiratory Syncytial Virus Pathogenesis.Frontiers in immunology · 2019Review
- Chemokine regulation of inflammation during respiratory syncytial virus infection.F1000Research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a common cause of upper respiratory tract infection in children and adults. However, infection with this virus sometimes leads to severe lower respiratory disease and is the major cause of infant hospitalisations in the developed world. Several risk factors such as baby prematurity and congenital heart disease are known to predispose towards severe disease but previously healthy, full-term infants can also develop bronchiolitis and viral pneumonia during RSV infection. The causes of severe disease are not fully understood but may include dysregulation of the immune response to the virus, resulting in excessive recruitment and activation of innate and adaptive immune cells that can cause damage. This review highlights recent discoveries on the balancing act of immune-mediated virus clearance versus immunopathology during RSV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.